Johnson & Johnson recalling 32M contraceptive packages outside US, says pregnancies unlikely

TRENTON, N.J. – Johnson & Johnson said Tuesday that it’s conducting a voluntary recall of millions of oral contraceptive packages in 43 countries outside the U.S., but that there’s a “very low” risk that the flawed tablets could cause unplanned pregnancies.

It’s the latest in a continuing string of about 40 product recalls announced by the New Brunswick, N.J., health care giant since 2009.

The birth control pills are being recalled — from pharmacies and wholesalers, but not women — because tests last month showed one of the two hormones in them was being released slower than it should.

The recall technically covers all 179 lots, or batches, of the contraceptive Cilest distributed since 2011 in Europe, Asia and Latin America. Each lot contains about 180,000 monthly contraceptive packages, meaning more than 32.2 million packages are covered. But only about 800,000 packages are estimated to still be in inventory at wholesalers and drugstores.

Medicine manufacturers are required to hold back samples from the lots they produce for periodic stability testing. While the two-year-old packages had been fine, tests last month showed that the female hormone in the pills, norgestimate, was no longer dissolving at the specified rate, said Michelle Romano, a spokeswoman for J&J’s Janssen Pharmaceuticals business. To be on the safe side, all the batches made since then were recalled, she said.

“There’s no impact on safety or efficacy. Women are not likely to get pregnant,” so the packages are not being recalled from individual consumers, Romano said. She said women with questions should contact their doctor.

J&J has been grappling with trying to upgrade manufacturing plants, including rebuilding a consumer health products factory from the ground up, while it slowly restores supply of recalled products to the market. The company is operating under an agreement with the Food and Drug Administration requiring increased inspections and oversight at the factories involved. And the lost product sales and the factory upgrades have cost J&J well over $1 billion.

The prior recalls mostly covered nonprescription medicines such as adult and children’s Tylenol and Motrin, but have included faulty hip implants, contact lenses, and a couple of prescription medicines. Reasons range from contamination with bacteria and incorrect levels of a drug’s active ingredient to liquid medicines that may contain metal particles and nauseating smells on containers.

J&J CEO Alex Gorsky and his predecessor, Bill Weldon, have pledged to resolve problems, but they continue.

Over the last four months, J&J has recalled Adept hip implants that were failing and had to be replaced prematurely, OneTouch VerioIQ blood glucose meters that shut off rather than issuing a warning when blood sugar levels get dangerously high, Children’s Tylenol made in South Korea that contained too much acetaminophen and versions of K-Y Jelly personal lubricant that potentially never got required regulatory approval.

“They haven’t fixed their manufacturing and their quality control problems,” Erik Gordon, a pharmaceuticals analyst and a professor at University of Michigan’s Ross School of Business, wrote in an email interview.

In trading Tuesday, J&J shares fell 61 cents to $84.10.


Follow Linda A. Johnson at http://twitter.comLindaJ_onPharma.